drugset / Trial / NCT04667637

Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Edaravone Dexborneol

NCT04667637

Phase 2 Completed 200 enrolled Huisheng Chen
RandomizedParallel-groupDouble-blindTreatment

Summary

To explore the safety and efficacy of edaravone dexborneol for the treatment of acute ischemic stroke patients who received endovascular thrombectomy.

Timeline

Start
2021-02-23
Primary completion
2022-10-10
Completion
2022-10-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Edaravone Dexborneol Unknown 37.5 mg Intravenous

Indications